×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 2: Strategy for Biosimilar Development & Approval
Session Chair(s)
Hee Kyung Kim, MBA, RPh
Sr. Vice President
Samsung Bioepis, Korea, Republic of
Speaker(s)
Session 2.1 : Challenges in the Global Clinical Development of Biological Products
SuEun Song
CELLTRION, Korea, Republic of
Head of Clinical Operation
Session 2.2 :Establishing Biosimilarity : Totality of Evidence
Se Eun Kim, MPH, RN
MFDS , Korea, Republic of
Director- Cell and Gene Therapy Products Division, NIFDS
Session 2.3 : Global Regulatory Development Strategy of Biosimilar
HyeJung Na
Samsung Bioepis, Korea, Republic of
Director
Session 2.4 :Biosimilars: Current Status and Future Trends
Hae-Young Ahn, PhD
Ahn Bio, United States
President
Have an account?